06 October 2010
By Anuradha Mascarenha
Preliminary findings of phase I AIDS vaccine trial, under way at Pune’s National AIDS Research Institute and Chennai’s Tuberculosis Research Centre (TRC), said the vaccine was safe.

The vaccine trial used ADVAX, a DNA’based vaccine, as the prime and Modified Vaccinia Ankara (MVA) as the boost. ADVAX was earlier tested in the US and found to be safe. Similarly, MVA vector, which was earlier tested at the Chennai’based TRC in 2008, showed that the vaccine was safe.
According to Risbud, there were no serious adverse events that were reported during the trial. The trial will be completed after one more follow up visit of volunteers later this year. "The final results will be available next year," said Risbud.
The prime’boost vaccine has shown only a modest immune response. According to Risbud, priming is to give one type of vaccine dose to induce certain kind of immune response, to be followed by or together with a second type of vaccine (booster). A primeboost combination may induce different types of immune responses and/or enhance overall responses beyond those seen with only one type of vaccine. The magnitude of the immune response was only modest. "A vaccine can be called efficacious when the immune responses are seen in a large number of volunteers and are persistent," said researchers.
Disclaimer: The news story on this page is the copyright of the cited publication. This has been reproduced here for visitors to review, comment on and discuss. This is in keeping with the principle of ‘Fair dealing’ or ‘Fair use’. Visitors may click on the publication name, in the news story, to visit the original article as it appears on the publication’s website.